Adopting Creative Chemistry to Optimize Bioprocessing Workflow

Why It Matters

Improving ADC stability directly reduces batch failures and enhances therapeutic efficacy, accelerating time‑to‑market for high‑value oncology drugs. The innovations also lower manufacturing costs by replacing time‑intensive chromatography with faster filtration steps.

Key Takeaways

• ADCs absorb >280 nm, causing light‑induced aggregation.
• Host cell enzymes can prematurely cleave ADC linkers during production.
• Dim or red light reduces photochemical damage in bioprocessing.
• New platform targets HCP contaminants to protect linker stability.
• Filtration may replace chromatography for faster impurity removal.

Pulse Analysis

The antibody‑drug conjugate (ADC) market is projected to exceed $10 billion by 2028, driven by a pipeline of targeted cancer therapies. Yet ADCs differ from conventional monoclonal antibodies in that they carry cytotoxic payloads linked through chemically labile bridges. This architecture makes them unusually sensitive to photochemical reactions and to enzymatic cleavage by host‑cell proteins (HCPs) during upstream and downstream processing. Even minor aggregation or premature linker release can trigger product loss, immunogenicity concerns, and costly batch rejections, underscoring the need for more resilient bioprocessing strategies.

At the forefront of addressing these vulnerabilities, Professor Sunny Zhou of Northeastern University and his collaborators—including Takeda—are pioneering a suite of ‘creative chemistry’ interventions. By shifting production lighting to yellow or red spectra, they suppress the >280 nm absorption that drives cross‑linking and aggregation. Simultaneously, their universal platform screens for HCP enzymes capable of cleaving ADC linkers and implements targeted removal steps, such as selective filtration, to safeguard linker integrity. Early industrial trials have shown measurable reductions in light‑induced modifications and improved linker stability throughout storage.

The shift toward low‑light, filtration‑centric workflows could reshape ADC manufacturing economics. Replacing conventional chromatography with rapid membrane filtration not only cuts processing time but also reduces solvent consumption and capital equipment footprints. Moreover, a more stable linker translates into longer circulatory half‑life, potentially enhancing clinical efficacy and dosing flexibility. As regulatory agencies tighten guidance on product purity, the adoption of these chemistry‑driven controls is likely to become a competitive differentiator for biopharma firms seeking to accelerate ADC pipelines while controlling cost.